Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 7/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599300 | 0.89 | PTK2B (0.58) | ACLYPTGES2PTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599318 | 0.86 | ACLY (0.50) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599399 | 0.77 | PTK2B (0.57) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599374 | 0.76 | PTK2B (0.56) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599384 | 0.76 | PTK2B (0.53) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599315 | 0.75 | PTK2B (0.53) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599387 | 0.74 | FABP4 (0.56) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599333 | 0.74 | PTK2B (0.52) | ACLYPTK2BSMN1; SMN2FABP4 | |
| SCHEMBL17599379 | 0.74 | ACLY (0.54) | ACLYPTGES2PTK2BSMN1; SMN2BRD4 | |
| SCHEMBL29907245 | 0.73 | PTGES2 (0.56) | ACLYPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |